ClinicalTrials.gg
RecruitingNCT07327723rPMS CTSUpdated Nov 3, 2026

Effects of Repetitive Peripheral Magnetic Stimulation(rPMS) on CTS(Carpal Tunnel Syndrome)

An interventional study of rPMS group and sham-rPMS in Carpal Tunnel Syndrome (CTS), sponsored by Ankara University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Ankara University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 3, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 130 studies in Carpal Tunnel Syndrome with a site in Turkey — 36 open to participants now, 41 under way, none of them phase 3. Carpal Tunnel Syndrome · Turkey.

Planned enrollment
58th of 82
40 · median 60
Started
2026
with 19 others
No phase
75 of 130
21 open now
Primary completion
2026-12
later than 28 of 40 live
Registered
97th of 130
by date

Among the 130 studies in Carpal Tunnel Syndrome with a site in Turkey, this one is the 58th largest by planned enrollment of the 82 interventional ones that give a count, is one of 20 that started in 2026, is one of 75 with no phase, reaches primary completion later than 28 of the 40 other live ones, and was the 97th registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

36 of the 130 studies in Carpal Tunnel Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Carpal Tunnel Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy, resulting from compression of the median nerve at the wrist. It is particularly common in middle-aged women. In the early stages, these patients frequently experience pain and numbness in the hand, especially in the first three fingers, and paresthesias, which often worsen at night. As the disease progresses, muscle weakness and atrophy of the thenar muscles can occur, severely impacting patients' daily activities and functionality. Clinical evaluation and patient complaints are crucial for diagnosis. Electrophysiological assessment tools such as nerve conduction studies and electromyography (EMG) are highly sensitive and considered the gold standard for confirming the diagnosis, assessing nerve damage, and determining the severity of this damage. In addition to electrophysiological assessment, ultrasonographic evaluation offers an important opportunity to observe structural changes in the median nerve associated with CTS.

In cases of mild to moderate CTS, nonsurgical treatments are the primary options for reducing symptoms; splinting, tendon-nerve gliding exercises, and physical therapy modalities are commonly preferred. Repetitive peripheral magnetic stimulation (rPMS) is a non-invasive method that can be applied to various tissues, such as spinal nerves, peripheral nerves, or muscles, and is used to reduce pain and improve motor function. While its potential benefits for many neurological diseases and musculoskeletal problems have been demonstrated in recent years, there are limited studies on the effectiveness of rPMS in patients with CTS. The primary objective of this study is to evaluate the effectiveness of rPMS on pain in individuals diagnosed with mild to moderate CTS. Secondarily, the effects of rPMS on symptom severity, functional status, nerve conduction parameters, and median nerve ultrasonographic findings will be analyzed. The findings of our study suggest that objective evaluation of rPMS treatment will contribute to supporting the clinical practice of this treatment option in patients with CTS with more comprehensive data.

Read the detailed description

This study is designed as a prospective, randomized, sham-controlled, double-blind, experimental study. It was approved by the Ethics Committee of Ankara University, Faculty of Medicine, and will be conducted in accordance with the Declaration of Helsinki. The study will be conducted at the Department of Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine Hospital. Eligible participants who are over 18 years of age, have provided informed consent, and have clinical symptoms and physical examination findings consistent with carpal tunnel syndrome (CTS), along with electrodiagnostic confirmation of mild to moderate CTS, will be enrolled. Participants will randomly be assigned to two groups: a treatment group and a sham group. Randomization will be performed using the Random Allocation Software (RAS) program. All patients will be instructed in tendon and nerve gliding exercises by a physiotherapist. In addition to these exercises, the treatment group will undergo repetitive peripheral magnetic stimulation (rPMS) therapy three times per week for two consecutive weeks, for a total of six sessions. Each session will last 10 minutes. rPMS will be applied by a physiotherapist who is blinded to the participants' diagnoses and outcome evaluations. All participants will be carefully monitored throughout the intervention period. Assessments will be conducted at three time points: baseline, three weeks after the final treatment session, and six weeks post-treatment. Participants will be assessed by Dr. Sema Köylü Dağ, who will be blinded to patient group allocation and diagnosis, using the case report form. In line with this form, sociodemographic data, including age, sex, height, weight, body mass index (BMI), marital status, educational level, occupation, and contact information, will be recorded, along with medical history, symptom duration, smoking status, dominant hand, and affected hand. Assessments will include the Visual Analog Scale (VAS), grip and pinch strength measurements (kg), the Boston Carpal Tunnel Questionnaire (BCTQ), the Short Form-36 Health Survey (SF-36), electrophysiological evaluation of the median nerve, and ultrasonographic cross-sectional area measurement (mm²) of the median nerve.

Statistical Analysis Sample size was calculated based on the primary endpoint: detecting a clinically meaningful difference in Visual Analog Scale (VAS) scores between the two groups, with a mean effect size of 1.4. Assuming a significance level of α = 0.05 and power = 0.95, the required sample size was calculated as 15 patients per group (30 patients in total). Calculations were performed using the GPower 3.1 software. Considering possible dropouts, the plan is to recruit 20 participants per group, totaling 40 patients.

Descriptive statistics will be presented as mean ± standard deviation, median (minimum-maximum), and frequency (percentage).

For between-group comparisons, Student's t-test and chi-square test will be used.

For within-group comparisons, repeated measures ANOVA or the Friedman test will be employed.

Correlations between variables will be analyzed using Pearson correlation coefficient.

A p-value \< 0.05 will be considered statistically significant

03

Conditions studied

  • Carpal Tunnel Syndrome (CTS)

Keywords

  • Carpal Tunnel Syndrome
  • Repetitive Peripheral Magnetic Stimulation
  • electrodiagnosis
  • ultrasound
  • functional status
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation with signed
  • Presence of symptoms consistent with carpal tunnel syndrome (CTS) (pain and/or paresthesia in the median nerve distribution), clinical signs (i.e., positive Tinel's and/or Phalen's test results), and electrodiagnostic findings (demonstrating mild to moderate CTS based on sensory or motor conduction studies of the median nerve)

Exclusion criteria

Exclusion Criteria:

  • Electrodiagnostic evidence of severe CTS
  • Abnormal ulnar nerve conduction findings
  • History of surgery for CTS
  • History of physical therapy or injection for CTS within the past 6 months
  • History of wrist fracture
  • Presence of other conditions causing similar symptoms, such as polyneuropathy, cervical radiculopathy, ulnar neuropathy, brachial plexopathy, or thoracic outlet syndrome
  • Central nervous system disorders (e.g., stroke, multiple sclerosis, Parkinson's disease)
  • Pregnancy
  • Presence of risk factors for CTS such as rheumatologic diseases, chronic kidney disease, diabetes mellitus, or hypothyroidism
  • to rPMS (e.g., pacemaker, cochlear implant)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    rPMS group

    All patients will be instructed in tendon and nerve gliding exercises by a physiotherapist. In addition to these exercises, the treatment group will undergo repetitive peripheral magnetic stimulation (rPMS) therapy three times per week for two consecutive weeks, for a total of six sessions. Each session will last 10 minutes

    Device: rPMS group

  • Sham comparator
    sham- rPMS group

    All patients will be instructed in tendon and nerve gliding exercises by a physiotherapist. In addition to these exercises, the sham-rPMS group will receive sham repetitive peripheral magnetic stimulation (rPMS) therapy, three times per week for two weeks, totaling six sessions. Each session will last 10 minutes. Patients will be positioned identically, and the device will be placed in the same position but not activated. Instead, previously recorded operational sounds of the device will be played back during the same duration to simulate the treatment experience.

    Device: sham-rPMS

Interventions

  • DevicerPMS group

    All patients will be instructed in tendon and nerve gliding exercises by a physiotherapist. In addition to these exercises, the treatment group will undergo repetitive peripheral magnetic stimulation (rPMS) therapy three times per week for two consecutive weeks, for a total of six sessions. Each session will last 10 minutes. The rPMS treatment will be administered using the BTL-6000 Super Inductive System Elite device. From the device interface, the "wrist/hand" region will be selected, and the "carpal tunnel syndrome" protocol pre-programmed for this region will be applied. During the procedure, patients will be instructed to lie supine or sit in a relaxed position to ensure complete muscle relaxation in the arm. The applicator will be positioned on the volar aspect of the wrist, aligned with the carpal tunnel, as close to the skin as possible. The frequency will be set between 5-50 Hz, and intensity will be adjusted to elicit visibly observable muscle contractions.

  • Devicesham-rPMS

    In the sham group, patients will be positioned identically, and the device will be placed in the same position but not activated. Instead, previously recorded operational sounds of the device will be played back during the same duration to simulate the treatment experience. All participants will be closely monitored throughout the treatment period

06

What researchers measure

Primary outcomes

  1. Visual analog scale (VAS)

    The Visual Analog Scale is a tool used to quantitatively assess pain intensity. It consists of a 10 cm horizontal line, with opposing descriptors at each end. The left end represents "no pain," and the right end represents "worst imaginable pain." Patients are asked to mark a point along the line that best represents the average level of pain they experience. The distance from the left endpoint to the point marked by the participant will be measured in centimeters and recorded as a VAS pain score.

    Time frame: Baseline, three weeks after the final treatment session, and six weeks post-treatment.

Secondary outcomes

  1. Grip and Pinch Strength Assessment

    Grip and pinch strength measurements are used to evaluate hand function and to quantitatively monitor progress throughout the treatment process. Grip strength is measured with the patient seated, shoulder adducted and neutrally rotated, elbow flexed at 90°, and the wrist in a neutral position. A Jamar dynamometer is used, and the average of three consecutive measurements is recorded. The same arm positioning is used for the pinch strength assessment. Three types of pinch are evaluated with a pinch gauge. Palmar pinch is assessed by bringing the thumb, index, and middle fingertips together. Lateral pinch is performed by pressing the distal phalanx of the thumb against the lateral surface of the middle phalanx of the index finger. Tip-to-tip pinch is evaluated by forming an "O" shape with the tips of the thumb and index finger. Each measurement is performed three times, and the average is recorded as kilograms (kg).

    Time frame: baseline, three weeks after the final treatment session, and six weeks post-treatment.

  2. Boston Carpal Tunnel Questionnaire (BCTQ)

    The BCTQ is designed to evaluate symptom severity and functional status in patients with carpal tunnel syndrome. The questionnaire consists of two sections. The Symptom Severity Scale includes 11 items that evaluate the intensity, character, frequency, and duration of symptoms. Each item is rated on a scale from 1 (mildest) to 5 (most severe), and the final score is calculated as the arithmetic mean of all item scores. The Functional Status Scale comprises 8 items assessing the level of difficulty experienced in performing daily activities. Similar to the symptom scale, each item is scored between 1 and 5, and the average of these scores constitutes the final result. Higher scores in both sections indicate more severe symptoms and greater functional impairment.

    Time frame: baseline, three weeks after the final treatment session, and six weeks post-treatment.

  3. SF-36 (Short Form-36 Health Survey Questionnaire)

    The SF-36 is a multidimensional questionnaire originally developed in the United States to evaluate general health status. The SF-36 consists of 36 items grouped into eight health domains, including physical functioning, role limitations due to physical and emotional problems, pain, general health perception, mental health, social functioning, and energy/fatigue.Each domain is scored on a 0-100 scale, where higher scores indicate better health status, lower scores reflect greater disability or poorer quality of life

    Time frame: baseline, three weeks after the final treatment session, and six weeks post-treatment.

  4. Electrophysiological Evaluation

    All measurements will be performed at room temperature using the Keypoint®-Dantec EMG system available in our clinic. The patient will be positioned supine with the palm facing upward. For motor conduction studies, the active electrode will be placed over the abductor pollicis brevis muscle, and the reference electrode over the proximal phalanx of the thumb. Stimulation will be applied 8 cm proximally, and measurements will include distal motor latency (ms) and compound muscle action potential (CMAP, mV). For sensory conduction studies, the active electrode will be placed over the proximal phalanx of the index finger, and the reference electrode about 3-4 cm distally. Sensory conduction will be assessed orthodromically at the Digit 1-wrist, Digit 2-wrist, Palm-wrist, Digit 3-wrist, and Wrist-elbow segments.Measurements will include distal sensory latency (ms), sensory nerve action potential amplitude (SNAP, µV), and conduction velocity.

    Time frame: baseline, three weeks after the final treatment session, and six weeks post-treatment.

  5. Ultrasonographic Measurement of Median Nerve Cross-Sectional Area

    The cross-sectional area of the median nerve will be assessed using an ultrasound (GE Healthcare Versana Premier) with a 7-12 MHz linear transducer. The forearm will be positioned in supination with the palm facing upward. At the level of the carpal tunnel, the area will be measured using manual tracing along the hyperechoic inner border of the nerve. The arithmetic mean of three consecutive measurements will be calculated and recorded in mm².

    Time frame: baseline, three weeks after the final treatment session, and six weeks post-treatment.

07

Study locations

1 of 1 sites recruiting
  • Ankara University, Faculty of Medicine, Cebeci Hospital, Cebeci
    Ankara, Mamak 06620, Turkey (Türkiye)
    Recruiting
    • Seçilay Güneş, Associated Professor · Contactyalices@hotmail.com · 03125082822
    • Seçilay Güneş, Associated Professor · Principal investigator
    • Sema Köylü Dağ, Research assistant (MD) · Sub investigator
    • Derya Gökmen, Professor · Sub investigator
    • Şehim Kutlay, Professor · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 11 months is close to that.

Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Jan 8, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Jan 15, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
Ankara University, Faculty of Medicine, Cebeci Hospital, Cebeci is now Recruiting
Nov 3, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Ankara University, Faculty of Medicine, Cebeci Hospital, Cebeci · Ankara, Turkey (Türkiye)Contact added y•••@hotmail.com · •••2822Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Not yet recruiting→Recruiting
    Ankara University, Faculty of Medicine, Cebeci Hospital, Cebeci is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Ankara University, Faculty of Medicine, Cebeci Hospital, Cebeci · Ankara, Turkey (Türkiye)Contact added y•••@hotmail.com · •••2822Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07327723
Lead sponsor
Ankara University
Responsible party
Seçilay Güneş (Associated Professor, Ankara University) — Principal investigator
First posted
Jan 8, 2026
Start date
Jan 1, 2026
Primary completion
Dec 15, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Seçilay Güneş, Associated Professor
Contact
yalices@hotmail.com
+905325562057
Sema Köylü Dağ, Research assistant (MD)
Contact
semakoylu@gmail.com
03125082822

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion